1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cardiometabolic Drug News OCTOBER 2014

Cardiometabolic Drug News OCTOBER 2014

  • October 2014
  • -
  • Espicom Business Intelligence
  • -
  • 25 pages

Industry Trend Analysis - Lilly's Trulicity Approval To Pave Way For Medium-Term GLP-1 Market Domination
Industry Brief - Pfizer/Astellas Terminate Co-Promotion/Distribution Agreement In Japan
Industry Brief - Sanofi/MyoKardia Collaborate To Develop Targeted Therapies For Cardiomyopathies
Industry Brief - Genfit/Sanofi Extend Drug-Discovery Collaboration
Industry Brief - MannKind/Sanofi Close Global Licensing Deal For Afrezza
Industry Trend Analysis - Pricing Strategy Expected To Determine Afrezza's Future
Industry Brief - Perosphere/Daiichi Sankyo Collaborate On Phase III Studies Of PER977 With Edoxaban
Industry Brief - MedImmune In-Licenses Shionogi's Biologic Programme For ACS
Industry Brief - Cytori To Restructure Operations And Reduce Costs
Industry Brief - Oxygen Biotherapeutics Changes Name To Tenax Therapeutics
Industry Brief - Islet Sciences/BHV Pharma Plan Merger To Create Avogenx
Industry Brief - Regado Reduces Workforce/Provides Update On Strategic Direction
Industry Trend Analysis - FDA-Approved Contrave Enters Tough And Competitive Market
Industry Brief - Novo Nordisk's Xultophy Approved In Europe For Type II Diabetes
Industry Brief - FDA Approves Epaned For Treating HF/Asymptomatic Left Ventricular Dysfunction
Industry Brief - FDA Panel Votes In Favour Of Liraglutide Approval For Obesity
Industry Brief - Bydureon Diabetes II Pen Available In US Pharmacies
Industry Brief - Daiichi Sankyo Gains Japanese Approval For Additional Indications Of Lixiana
Industry Brief - EC Approves Lilly's Humalog 200 Units/mL KwikPen
Industry Brief - Takeda Responds To Judgement In Actos Case
Industry Brief - Pradaxa Approved In Canada For Treating DVT/PE
Industry Brief - Mylan To Acquire US Arixtra Rights From Aspen
Industry Brief - Jury Favours Plaintiff In Takeda Diabetes Drug Case
Industry Brief - CDRAC Votes Against Actavis’ Nebivolol+Valsartan NDA
Industry Brief - Zydus Gains US Glipizide Tentative Approval
Industry Brief - AMCo Launches Nicardipine, Nebivolol, In UK
Industry Brief - Arixtra Added To Navamedic’s Portfolio
Industry Trend Analysis - Novo Nordisk To Invest In Obesity Research With New Unit
Industry Brief - Merck Presents First Phase III Data In Japanese Patients For Omarigliptin
Industry Brief - Xarelto May Be Alternative To VKAs In AF Patients Undergoing Elective Cardioversion
Industry Brief - Mast Reports Positive Top-Line Results From AIR001 Phase II Study In PAH
Industry Brief - Novartis' LCZ696 Shows Superiority Over Enalapril In PARADIGM-HF
Industry Brief - First Patients Enrolled In Phase III LEVO-CTS Trial Of Levosimendan
Industry Brief - DSMB Recommends Continuation Of CHART-1 Phase III Trial
Industry Brief - Positive Results Reported From Four Phase III Trials Of Alirocumab
Industry Brief - Empaglifozin/Linagliptin Combination Shows Sustained Efficacy In Phase III Trials
Industry Brief - Janssen/Bayer Expand EXPLORER Cardiovascular Programme For Xarelto
Industry Brief - Amgen Presents Analyses Of Ivabradine Phase III Study Data For Treating cHF
Industry Brief - AstraZeneca's Once-Weekly Exenatide Shows Superiority Over Twice-Daily Byetta
Industry Brief - Trelagliptin Phase III Trial Results Highlighted At EASD
Industry Brief - Positive Interim Data From ITCA 650 Phase III Trial Highlighted
Industry Brief - Zealand Provides Clinical data On Lyxumia/LixiLan And Additional Updates At EASD
Industry Brief - Esperion's ETC-1002 Phase IIb Study Meets Primary Endpoint
Industry Brief - Positive Top-Line Results From ITCA 650 Phase III Trials Released
Industry Brief - Zafgen Initiates Beloranib Phase III Trial In PWS
Industry Brief - Phase III Study Of Andexanet Alfa/Eliquis Meets Primary/Secondary Endpoints
Industry Brief - AnGes Initiates Global Phase III Trials Of Collategene In Critical Limb Ischaemia
Industry Brief - Byetta Meets Primary Endpoint In Trial Versus Bolus Insulin

Table Of Contents

Cardiometabolic Drug News OCTOBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.